Loading
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Latest filing published 22 Sept 2020 for Metacrine, Inc., €2.5M.
Filing timeline
BuySaleRobert J. Adelman
Insider track record
Disclosed buys
5
Disclosed sells
0
Signal history
Closed purchases
Market purchases
5
Positive at T+90
100%
Median T+90
+47.1%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +104.2%Entry US$29.36 · Close at T+365 US$59.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Robert J. Adelman: trading record in brief
This profile gathers the share dealings of Robert J. Adelman across 4 companies, led by ALX Oncology Holdings Inc, ARYx Therapeutics, Inc. and Volcano Corp. The record holds 15 filings, for trades running from 20 June 2006 to 18 September 2020.
No open-market sale appears; the market trades are 5 purchases worth €18.6M. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2020 alone, the filings show 3 purchases and no sales.
Half of the purchases are above €2.3M and half below. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.
The latest filing, published on 22 September 2020, reports an open-market purchase of €2.5M in Metacrine, Inc. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Robert J. Adelman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
230,000 shares@ US$13.00100.0% of flowCommon StockSEC:0000905148-20-001038:0
Canonical exit: 17 Dec 2020 (T+90)
2,829,123 sharesCommon StockSEC:0000905148-20-001038:1
850,000 shares@ US$19.0099.6% of flowCommon StockSEC:0000905148-20-000827:3
Canonical exit: 19 Oct 2020 (T+90)
3,000 shares@ US$19.000.4% of flowCommon StockSEC:0000905148-20-000827:4
Canonical exit: 19 Oct 2020 (T+90)
78,175 sharesCommon StockSEC:0000905148-20-000827:0
3,100,020 sharesCommon StockSEC:0000905148-20-000827:1
3,941,949 sharesCommon StockSEC:0000905148-20-000827:2
1,214,646 sharesCommon StockSEC:0001179110-08-019630:0
Canonical exit: 12 Feb 2009 (T+90)
897,866 sharesCommon StockSEC:0001104659-07-083226:1
604,228 sharesCommon StockSEC:0001104659-07-083226:2
323,399 sharesCommon StockSEC:0001104659-07-083226:3
195,705 sharesCommon StockSEC:0001209191-06-037380:2
1,578,832 sharesCommon StockSEC:0001209191-06-037380:0
591,146 sharesCommon StockSEC:0001209191-06-037380:1
14 of 14 declarations
